General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Valfix(SIGNIFICANT), Ancora(SIGNIFICANT), HeartFlow(SIGNIFICANT), Ablative Solutions(SIGNIFICANT), Elucid Bioimaging(SIGNIFICANT), Occlutech(SIGNIFICANT), Impulse Dynamics(SIGNIFICANT), Adona Medical(SIGNIFICANT), Millennia Biopharma(SIGNIFICANT), Cardiac Success(SIGNIFICANT), Oxitope(SIGNIFICANT), HighLife(SIGNIFICANT), Elixir(SIGNIFICANT), Abbott(SIGNIFICANT), Remote Cardiac Enablement(SIGNIFICANT), Aria(SIGNIFICANT), Zoll(SIGNIFICANT), Shockwave(SIGNIFICANT), Alleviant(SIGNIFICANT), FBR Medical(SIGNIFICANT), Myochron(SIGNIFICANT), Colibri(SIGNIFICANT), Bioventrix(SIGNIFICANT), MedHub(SIGNIFICANT) EQUITY INTERESTS/STOCK OPTIONS: Orchestra Biomed(SIGNIFICANT), Ancora(SIGNIFICANT), Applied Therapeutics(SIGNIFICANT), Aria(SIGNIFICANT), Biostar family funds(SIGNIFICANT), Cagent(SIGNIFICANT), Cardiac Success(SIGNIFICANT), Spectrawave(SIGNIFICANT), Valfix(SIGNIFICANT), Xenter(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Abiomed(SIGNIFICANT), Abbott(SIGNIFICANT), Shockwave(SIGNIFICANT), Pulnovo(SIGNIFICANT), Phillips(NONE), Cardiovascular Systems Inc.(SIGNIFICANT), Biosense Webster(SIGNIFICANT), Bioventrix(SIGNIFICANT), V-wave(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Vascular Dynamics(SIGNIFICANT), Abiomed(SIGNIFICANT)

View Full Disclosure